Huakang Biomedical Holdings Company Limited (HK:8622)

:8622

8622

Huakang Biomedical Holdings Company Limited

RESEARCH TOOLSreports

Want to see HK:8622 full AI Analyst Report?

Huakang Biomedical Holdings Company Limited (8622) Price & Analysis

0 Followers

8622 Stock Chart & Stats

HK$0.42

HK$0.01(7.32%)

At close: Jan 09 4:00 PM EST

HK$0.42

HK$0.01(7.32%)

Day’s Range― - ―

52-Week RangeHK$0.20 - HK$0.75

Previous CloseN/A

Volume952.00K

Average Volume (3M)2.14M

Market Cap

HK$112.37M

Enterprise ValueHK$65.51M

Total Cash (Recent Filing)HK$36.73M

Total Debt (Recent Filing)HK$6.42M

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Aug 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding515,472,000

10 Day Avg. Volume1,472,000

30 Day Avg. Volume2,141,866

Financial Highlights & Ratios

PEG Ratio-2.40

Price to Book (P/B)3.83

Price to Sales (P/S)6.93

P/FCF Ratio-59.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Product-level MarginsA ~63% gross margin indicates durable product-level economics and pricing power versus direct costs. This supports long-term profitability potential if overheads are controlled and product mix sustains, making future margin recovery more achievable once operating leverage improves.

Modest, Consistent Revenue GrowthRepeated year-on-year top-line growth signals market traction and stable demand for the company’s offerings. Even modest organic growth helps scale fixed costs and can underpin improved margins over 2–6 months if cost discipline or commercial expansion continues.

Conservative LeverageLow leverage reduces solvency and refinancing risk, giving the company flexibility to fund operations or R&D through its balance sheet. This conservatism is a lasting structural strength that cushions cash-burn periods and potential external funding needs.

Bears Say

Persistent Operating LossesSustained negative operating margins show core expenses outpacing gross profit, indicating structural profitability issues. Without material cuts, higher revenue, or product mix shifts, losses will continue to erode equity and impair long-term viability over the medium term.

Negative Operating And Free Cash FlowTwo consecutive years of negative operating and free cash flow create persistent funding needs and increase reliance on balance-sheet resources or external capital. This structural cash burn raises sustainability risk and may force dilutive financing or cutbacks if not reversed.

Declining Equity & Negative ROEFalling shareholder equity and a negative ROE reflect cumulative losses impairing book value. This trend signals weakened capital position and reduces buffer against future shocks, limiting the company's ability to invest or withstand prolonged cash deficits.

8622 FAQ

What was Huakang Biomedical Holdings Company Limited’s price range in the past 12 months?

Huakang Biomedical Holdings Company Limited lowest stock price was HK$0.20 and its highest was HK$0.75 in the past 12 months.

What is Huakang Biomedical Holdings Company Limited’s market cap?

Huakang Biomedical Holdings Company Limited’s market cap is HK$112.37M.

When is Huakang Biomedical Holdings Company Limited’s upcoming earnings report date?

Huakang Biomedical Holdings Company Limited’s upcoming earnings report date is Aug 11, 2026 which is in 60 days.

How were Huakang Biomedical Holdings Company Limited’s earnings last quarter?

Huakang Biomedical Holdings Company Limited released its earnings results on Mar 27, 2026. The company reported -HK$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.006.

Is Huakang Biomedical Holdings Company Limited overvalued?

According to Wall Street analysts Huakang Biomedical Holdings Company Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Huakang Biomedical Holdings Company Limited pay dividends?

Huakang Biomedical Holdings Company Limited does not currently pay dividends.

What is Huakang Biomedical Holdings Company Limited’s EPS estimate?

Huakang Biomedical Holdings Company Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Huakang Biomedical Holdings Company Limited have?

Huakang Biomedical Holdings Company Limited has 515,472,000 shares outstanding.

What happened to Huakang Biomedical Holdings Company Limited’s price movement after its last earnings report?

Huakang Biomedical Holdings Company Limited reported an EPS of -HK$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.

Which hedge fund is a major shareholder of Huakang Biomedical Holdings Company Limited?

Currently, no hedge funds are holding shares in HK:8622

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Huakang Biomedical Holdings Company Limited Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

-9.57%

Trailing 12-Months

Asset Growth

6.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Huakang Biomedical Holdings Company Limited

Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.